Patient characteristics of the study population with different stages of liver fibrosis.

<p>Ages, body mass index values, AST, ALT, bilirubin levels and platelet counts are presented as mean ± 1 Standard Deviation.</p><p>ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase;</p><p>^aAST reference value: 38 U/l (men), 32 U/l(women)</p><p>^bALT reference values: 45 U/l (men), 40 U/l(women); ULN: upper limit of normal</p><p>Patient characteristics of the study population with different stages of liver fibrosis.</p

ROC analysis to determine the accuracy of MRE and APRI in predicting METAVIR fibrosis stage in patients with HBV or HCV.

<p>MRE = MR Elastography; Az = area under the curve; kPa = kilopascal; Sn, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; -LR, negative likelihood ratio;</p><p>Concordance represents the rate of patients who were classified correctly (true positive + true negative).</p><p>^a Represents the comparison of the diagnostic performance of MRE and APRI in all patients for each corresponding fibrosis stage.</p><p>^b Represents the comparison of the diagnostic performance of MRE between patients with HBV and HCV for each corresponding fibrosis stage.</p><p>ROC analysis to determine the accuracy of MRE and APRI in predicting METAVIR fibrosis stage in patients with HBV or HCV.</p

Optimal liver stiffness cutoff values measured by MR Elastography for different degrees of liver fibrosis.

<p>kPa, kilopascal; Sn, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; LR (+), positive likelihood ratio; LR (-), negative likelihood ratio.</p><p>Concordance represents the rate of patients who were classified correctly (true positive + true negative).</p><p>*Sn, 100% sensitivity; Sn+Sp, a maximum sum of sensitivity and specificity; Sp, 100% specificity.</p><p>Optimal liver stiffness cutoff values measured by MR Elastography for different degrees of liver fibrosis.</p

Flow diagram of patient selection.

<p>HBV = chronic hepatitis B; HCV = chronic hepatitis C; APRI = aspartate aminotransferase to the platelet ratio index; MRE = MR elastography.</p

Box plots.

<p>(a) liver stiffness values measured by MRE and (b) APRI values according to each METAVIR fibrosis stage (F0 to F4). The mean liver stiffness scores and APRI values increased with increasing METAVIR stage of fibrosis. (Spearman’s risk correlation coefficient = 0.85 and 0.42, respectively) The horizontal line through each box represents the median and each box represents data from the 25^th to the 75^th percentile. The separate asterisks and circles represent outliers.</p

Influences of clinical, biological and histolopathological parameters on liver stiffness measurement using MR Elastography.

<p>The results of the univariate and multivariate linear analyses are expressed as unstandardized B coefficients with 95% confidence intervals.</p><p>Influences of clinical, biological and histolopathological parameters on liver stiffness measurement using MR Elastography.</p

Analysis of the effect of liver steatosis on liver stiffness estimated by MR Elastogrpahy for each fibrosis stage.

<p>Values are depicted as mean ± standard deviation. kPa = kilopascal.</p><p>Analysis of the effect of liver steatosis on liver stiffness estimated by MR Elastogrpahy for each fibrosis stage.</p

MRE data in a 46-year-old female with hepatitis B.

<p>(a) magnitude image,.(b) wave image, (c) stiffness map, and (d) confidence map. All images are at the same level. The dotted lines on the confidence maps represent the liver outlines of the corresponding patient’s MR images. The overall mean stiffness value on a total of 5 MRE images was 2.34 kPa. Liver biopsy confirmed fibrosis stage F1.</p

Proposed clinical algorithm of liver stiffness measured by MR Elastography in patients with HBV and those with HCV.

<p>Proposed clinical algorithm of liver stiffness measured by MR Elastography in patients with HBV and those with HCV.</p

Adjusted associations between plasma IL-6 levels and poor 30-day outcome.

<p>*: Adjusted for dichotomized age, Glasgow Coma Scale on day 0, and vasospasm and Fisher grades according to the receiver operating characteristic analyses.</p><p>Abbreviations: IL-6: interleukin-6; mRS: modified Rankin Scale.</p><p>Adjusted associations between plasma IL-6 levels and poor 30-day outcome.</p